$2.23 Billion is the total value of Vivo Capital, LLC's 60 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $121,233,000 | -39.6% | 760,606 | -50.2% | 5.44% | -37.4% |
| KDMN | Sell | Kadmon Holdings Inc | $37,305,000 | +65.7% | 4,283,014 | -26.4% | 1.68% | +71.8% |
| KALV | Sell | KalVista Pharmaceuticals Inc. | $28,651,000 | -35.8% | 1,641,913 | -11.9% | 1.29% | -33.5% |
| CLDX | Sell | Celldex Therapeutics Inc | $26,156,000 | -19.3% | 484,453 | -50.0% | 1.17% | -16.3% |
| LEGN | Sell | Legend Biotech Corp Sponsoredsponsored ads | $24,711,000 | -37.1% | 488,751 | -48.9% | 1.11% | -34.7% |
| ZLAB | Sell | Zai Lab Ltd ADRadr | $18,443,000 | -40.5% | 174,999 | -0.0% | 0.83% | -38.3% |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $16,934,000 | -29.8% | 940,754 | -31.5% | 0.76% | -27.3% |
| VRNA | Sell | Verona Pharma PLCads | $15,070,000 | -24.4% | 2,749,918 | -9.8% | 0.68% | -21.6% |
| GRCL | Sell | Gracell Biotechnologies Incsponsored ads | $13,334,000 | -22.8% | 961,359 | -27.6% | 0.60% | -19.8% |
| CRNX | Sell | Crinetics Pharmaceuticals Inc | $10,889,000 | -67.0% | 517,280 | -70.5% | 0.49% | -65.8% |
| EPIX | Sell | Essa Pharma Inc | $8,449,000 | -80.9% | 1,056,067 | -31.9% | 0.38% | -80.3% |
| VALN | Sell | Valneva SEsponsored ads | $6,280,000 | -40.4% | 200,000 | -50.0% | 0.28% | -38.2% |
| PASG | Sell | Passage Bio Inc | $5,371,000 | -37.2% | 539,263 | -16.5% | 0.24% | -34.9% |
| LRMR | Sell | Larimar Therapeutics Inc | $4,610,000 | -41.3% | 399,830 | -50.0% | 0.21% | -39.1% |
| EIGR | Sell | Eiger BioPharmaceuticals Inc | $3,137,000 | -79.4% | 469,588 | -73.8% | 0.14% | -78.7% |
| TCDA | Sell | Tricida, Inc. | $779,000 | +3.2% | 167,863 | -3.9% | 0.04% | +6.1% |
| CALT | Exit | Calliditas Therapeutics ADRsponsored ads | $0 | – | -62,306 | -100.0% | -0.08% | – |
| IMVT | Exit | Immunovant Inc | $0 | – | -532,847 | -100.0% | -0.24% | – |
| CYTK | Exit | Cytokinetics Inc | $0 | – | -700,000 | -100.0% | -0.60% | – |
| NVAX | Exit | Novavax Inc | $0 | – | -88,046 | -100.0% | -0.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.